Mark A. Velleca
2023 - Black Diamond Therapeutics
In 2023, Mark A. Velleca earned a total compensation of $2.9M as President and Chief Executive Officer at Black Diamond Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $113,667 |
|---|---|
| Option Awards | $2,591,404 |
| Salary | $180,333 |
| Other | $63,950 |
| Total | $2,949,854 |
Velleca received $2.6M in option awards, accounting for 88% of the total pay in 2023.
Velleca also received $113.7K in non-equity incentive plan, $180.3K in salary and $64K in other compensation.
Rankings
In 2023, Mark A. Velleca's compensation ranked 315th out of 2,978 executives tracked by ExecPay. In other words, Velleca earned more than 89.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 315 out of 2,978 | 89th |
Division Manufacturing | 173 out of 1,637 | 89th |
Major group Chemicals And Allied Products | 116 out of 906 | 87th |
Industry group Drugs | 113 out of 869 | 87th |
Industry Biological Products, Except Diagnostic Substances | 39 out of 211 | 82nd |
Source: SEC filing on April 24, 2024.
Velleca's colleagues
We found three more compensation records of executives who worked with Mark A. Velleca at Black Diamond Therapeutics in 2023.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019